Results 11 to 20 of about 17,802 (177)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Frontiers in Neuroscience, 2017
Objective: It is well-known that initiation of fingolimod induces a transient decrease of heart rate. However, the underlying cardiac autonomic regulation is poorly understood. We aimed to investigate the changes of autonomic activity caused by the first
Kai Li, Kai Li, Urszula Konofalska, Katja Akgün, Manja Reimann, Heinz Rüdiger, Rocco Haase, Tjalf Ziemssen, Tjalf Ziemssen   +8 more
doaj   +2 more sources

Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection [PDF]

Journal of Neuroinflammation, 2017
Background Fingolimod, a sphingosine-1-phosphate receptor modulator with well-described immunomodulatory properties involving peripheral immune cell trafficking, was the first oral agent approved for the treatment of relapsing remitting multiple ...
Björn Ambrosius, Kalliopi Pitarokoili, Lisa Schrewe, Xiomara Pedreiturria, Jeremias Motte, Ralf Gold   +5 more
doaj   +3 more sources

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations

Therapeutics and Clinical Risk Management, 2016
Ilya Ayzenberg, Robert Hoepner, Ingo Kleiter Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany Abstract: Fingolimod (FTY720), an immunotherapeutic drug targeting the sphingosine-1-phosphate receptor, is a widely used ...
Ayzenberg I, Hoepner R, Kleiter I
doaj   +1 more source

Preclinical characterisation of fingolimod as a potential therapeutic agent for stroke [PDF]

, 2022
Stroke is the leading cause for death and disability worldwide, and the search for novel drug treatments has been affected by repeated clinical trial failures.
Diaz Diaz, Andrea C.
core   +1 more source

Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro

, 2022
Charge-altering releasable transporters (CARTs) are a class of oligonucleotide delivery vehicles shown to be effective for delivery of messenger RNA (mRNA) both in vitro and in vivo.
Paul A. Wender (1321791), Trevor J. Del Castillo (12918246), Robert M. Waymouth (1325106), Ronald Levy (25981), Stefano Testa (668165), Timothy R. Blake (1956223), Ole A. W. Haabeth (6710606), Ranjani Rajapaksa (12918249), Debra K. Czerwinski (10994984)   +8 more
core   +1 more source

Fingolimod modulates microglial activation to augment markers of remyelination [PDF]

, 2011
Introduction Microglial activation in multiple sclerosis has been postulated to contribute to long-term neurodegeneration during disease. Fingolimod has been shown to impact on the relapsing remitting phase of disease by modulating autoreactive T-cell ...
Giovannoni Gavin, Jackson Samuel J, Jackson, SJ, Baker, D, Gavin Giovannoni, Baker David, Giovannoni, G, David Baker, Samuel J Jackson   +8 more
core   +1 more source

Biernacki-et-al.Real-world-data-on-the-efficacy-and-long-term-use-of-fingolimod-in-Hungary.xlsx

, 2022
Background: Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012.
Biernacki Tamás (12190799)
core   +1 more source

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

BMC Neurology, 2017
Background Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse.
Anat Achiron, Hany Aref, Jihad Inshasi, Mohamad Harb, Raed Alroughani, Mahendra Bijarnia, Kathryn Cooke, Ozgur Yuksel   +7 more
doaj   +1 more source

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK.
Gordon Mazibrada, Charlotte Sharples, Ines Perfect   +2 more
doaj   +1 more source

Aligned Fingolimod-Releasing Electrospun Fibers Increase Dorsal Root Ganglia Neurite Extension and Decrease Schwann Cell Expression of Promyelinating Factors

Frontiers in Bioengineering and Biotechnology, 2020
Researchers are investigating the use of biomaterials with aligned guidance cues, like those provided by aligned electrospun fibers, to facilitate axonal growth across critical-length peripheral nerve defects. To enhance the regenerative outcomes further,
Devan L. Puhl, Devan L. Puhl, Jessica L. Funnell, Jessica L. Funnell, Anthony R. D’Amato, Anthony R. D’Amato, Jonathan Bao, Jonathan Bao, Dmitri V. Zagorevski, Yelena Pressman, Daniel Morone, Daniel Morone, Agnes E. Haggerty, Martin Oudega, Martin Oudega, Martin Oudega, Martin Oudega, Ryan J. Gilbert, Ryan J. Gilbert   +18 more
doaj   +1 more source